PSNL
Personalis, Inc.
$15.79
+0.76 (+5.06%)
At close · Jul 15
Market Cap
$1.63B
Shares
104,721,098
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.79
Open$15.26
Day$14.85–16.07
52W$3.84–16.15
Avg vol 30d3.9M
Short int11.3M · 10.8% float · 2.8d
Short vol52%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+81%
above
Price vs 50-day avg
+54%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
97%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+61%
trailing
6-month return
+64%
trailing
YTD return
+98%
this year
Relative strength
+54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
2 of 142 funds reported for Jun 30 · net +8.3K sh shares
Insider flow
Distributing
Net -$2.0M over 90 days · 100% sells
Short interest
Rising
10.80% of float · ▲ +1.8% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
142 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-79.5M
Balance sheet
$119.2M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total company revenue
· full year 2026
Raised
$78M – $80M
prior FY $69.65M
midpoint +13.4% Y/Y
Clinical revenue
· full year 2026
Lowered
$10M – $11M
prior FY $69.65M
midpoint −84.9% Y/Y
Revenue from pharma testing services and all other customers
· full year 2026
Raised
$55M – $56M
prior FY $69.65M
midpoint −20.3% Y/Y
Revenue from population sequencing and enterprise sales
· full year 2026
Lowered
$13M
prior FY $69.65M
midpoint −81.3% Y/Y
Gross margin
· full year 2026
Initiated
15% – 20%
Net loss
· full year 2026
Initiated
$-105M
Cash usage
· full year 2026
Initiated
$100M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+81%
Bullish
Price vs 50-day avg
+54%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
2 of 142 funds reported for Jun 30 · net +8.3K sh shares
Insider flow
Distributing
Net -$2.0M over 90 days · 100% sells
Short interest
Rising
10.80% of float · ▲ +1.8% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
142 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $16 · 97%
52-wk high $16
vs 200-day avg +81%
vs 50-day avg +54%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Clinical test volume | 7,815 | Q1 2026 | — |
|
|
|||
| Clinical test volume growth (sequential) | 26% | Q1 2026 | — |
| Clinical test volume growth (year-over-year) | 258% | Q1 2026 | — |
| biopharma MRD revenue | $3.1M | Q1 FY2026 call | — |
| clinical tests delivered | 7,800 | Q1 FY2026 call | — |
| clinical tests sequential growth | 26% | Q1 FY2026 call | — |
| clinical tests year-over-year growth | 258% | Q1 FY2026 call | — |
| oncologist retention | 98% | Q1 FY2026 call | — |
| ordering physicians | 1,000 | Q1 FY2026 call | — |
| Cash, cash equivalents, and short-term investments | $240M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PSNL
this stock
Personalis, Inc.
|
$1.63B | +98.4% | -17.7% | — | 10.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$201.86B | -6.2% | +0.4% | 29.6 | 1.4% |
|
DHR
Danaher Corp /De/
|
$145.10B | -11.9% | +8.5% | 39.6 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$45.44B | -14.8% | +10.4% | 42.4 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.64B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PSNL | +11.9% | +61.3% | +63.6% | +17.8% | +98.4% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +10.7% | +61.5% | +53.5% | +16.8% | +87.7% |